Cat. No.: HY-N1109

Uvaol

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Uvaol, a triterpene present in olives and virgin olive oil, possesses anti-inflammatory properties and antioxidant effects. Uvaol is an orally active inducer of apoptosis in astroglioma cells. Uvaol also has anti-cancer activities. Uvaol attenuates pleuritis and eosinophilic inflammation in ovalbumin-induced allergy in mice.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.20%
CAS No.: 545-46-0
Formule: C₃₀H₅₀O₂
Masse moléculaire:442.72

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Uvaol Chemical Structure

CAS No.: 545-46-0

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	45 μM Compound: 19	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	>200 μM Compound: 2	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 38718553]
A549	IC₅₀	>316 μM Compound: 9	Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge	[PMID: 15730243]
A549	IC₅₀	>316 μM Compound: 9	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 15730243]
B16	ED₅₀	>50 μM Compound: 21	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	46.8 μM Compound: 21	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
CHO	EC₅₀	>10 μM Compound: Uvaol	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Uvaol	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DLD-1	IC₅₀	>200 μM Compound: 2	Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 38718553]
HCT-116	GI₅₀	37 μM Compound: 19	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HepG2	IC₅₀	214 μM Compound: 9	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	53.7 μM Compound: 10	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HT-29	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	>10 μM Compound: 10	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
J774	IC₅₀	155.8 μM Compound: 4	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
KB	IC₅₀	37.7 μM Compound: 10	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
Lu1	IC₅₀	53.3 μM Compound: 10	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	GI₅₀	93 μM Compound: 19	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	58.2 μM Compound: 10	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MDA-MB-231	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-435	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
OVCAR-3	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
RAW264.7	IC₅₀	>100 μM Compound: 1	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production	[PMID: 34973341]
RAW264.7	IC₅₀	>100 μM Compound: 1	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production	[PMID: 34973341]
WI-38	IC₅₀	11.8 μM Compound: 9	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	58.3 μM Compound: 9	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]

In Vitro

Uvaol (25-50 μM; for 6-18 h) induces morphological changes in 1321N1 astrocytoma cells in the cell morphology experiment, causing cells to contract, round up and detach from the culture support, and also alters the expression levels of cell-surface proteins ICAM-1, VCAM-1 and CD44^[2].
Uvaol (1-50 μM; for 18 h) inhibits DNA synthesis in 1321N1 astrocytoma cells in the cell proliferation experiment, showing a dose-dependent growth-inhibitory effect^[2].
Uvaol (25-100 μM; for 18 h) induces apoptosis in 1321N1 astrocytoma cells in the apoptosis experiment, resulting in a sub-diploid peak in the cell cycle, increasing the outer leaflet of phosphatidylserine on the cell surface, and the apoptotic rate increases in a dose-dependent manner^[2].
Uvaol (25-100 μM; 0.25-6 h) activates JNK in 1321N1 astrocytoma cells in the JNK activation experiment, and the activation is the strongest at 50 μM^[2].
Uvaol (5-50 μM; 6-18 h) promotes the accumulation of intracellular reactive oxygen species (ROS) and reduces the mitochondrial membrane potential in 1321N1 astrocytoma cells in the ROS production experiment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

1321N1 astrocytoma cells
Concentration:

1 μM, 5 μM, 25 μM, 50 μM
Incubation Time:

18 h
Result:

Showed a dose-dependent growth-inhibitory effect.

Apoptosis Analysis^[2]

Cell Line:

1321N1 astrocytoma cells
Concentration:

5 μM, 25 μM, 50 μM, 100 μM
Incubation Time:

18 h
Result:

Induced apoptosis in 1321N1 astrocytoma cells.

Cell Cycle Analysis^[2]

Cell Line:

1321N1 astrocytoma cells
Concentration:

25 μM, 50 μM, 100 μM
Incubation Time:

18 h
Result:

Revealed a progressive accumulation of cells in the subdipliod phase (sub-G1) of the cycle.

Western Blot Analysis^[2]

Cell Line:

1321N1 astrocytoma cells
Concentration:

25 μM, 50 μM, 100 μM
Incubation Time:

0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h
Result:

Led to the activation of JNK, with the maximum activation observed after 4 h of stimulation at 50 μM.

In Vivo

Uvaol (100-500 μmol/kg; orally administered; 60 min before antigen challenge) can reduce pleural eosinophilic inflammation and IL-5 concentration in a murine pleurisy model induced by ovalbumin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Swiss mice (weighing 25-30 g) with subcutaneous (s.c.) injection on days 0 and 7 with 0.2 mL of a solution containing 50 μg of Ovalbumins (OVA) (HY-W250978) adsorbed to 5 mg of aluminum hydroxide^[1].
Dosage:

100 μmol/kg, 200 μmol/kg, 500 μmol/kg (2% DMSO in sterile saline)
Administration:

Oral administration; 60 min before antigen challenge
Result:

Caused a significant decrease in total leukocyte accumulation.
Induced a significant reduction in the levels of this cytokine.

Chemical Information

CAS No. 545-46-0
Appearance Solid
Masse moléculaire 442.72
Formule C₃₀H₅₀O₂
Color White to off-white
SMILES

CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](CO)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Blood Coagul Fibrinolysis

Uvaol alleviates oxidative stress induced human umbilical vein endothelial cell injury by suppressing mitogen-activated protein kinase signaling pathway. [Abstract]

2024 Jul 1;35(5):248-255. PMID: 38700418

Solvant et solubilité

In Vitro:

Ethanol : 10 mg/mL (22.59 mM; ultrasonic and warming and heat to 60°C)

DMSO : 2 mg/mL (4.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2588 mL

11.2938 mL

22.5876 mL

5 mM

0.4518 mL

2.2588 mL

4.5175 mL

10 mM

0.2259 mL

1.1294 mL

2.2588 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: 1 mg/mL (2.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.26 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Agra LC, et al. Uvaol attenuates pleuritis and eosinophilic inflammation in ovalbumin-induced allergy in mice. Eur J Pharmacol. 2016 Jun 5;780:232-42. [Content Brief]

[2]. Martín R, et al. Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation. PLoS One. 2009 Jun 22;4(6):e5975. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.2588 mL	11.2938 mL	22.5876 mL	56.4691 mL
Ethanol	5 mM	0.4518 mL	2.2588 mL	4.5175 mL	11.2938 mL
	10 mM	0.2259 mL	1.1294 mL	2.2588 mL	5.6469 mL
	15 mM	0.1506 mL	0.7529 mL	1.5058 mL	3.7646 mL
	20 mM	0.1129 mL	0.5647 mL	1.1294 mL	2.8235 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Uvaol

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antioxidant Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Uvaol

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Uvaol Related Classifications

HY-N1109 Related Classifications